Rheumatology

Delivers comprehensive coverage of various aspects of clinical rheumatology. This volume includes three sections - Diagnosis, Rheumatic Diseases, and Pharmacopeia for Rheumatic Diseases - that addresses diagnosis and management for a range of adult and pediatric rheumatic disorders, including those of idiopathic, infectious, and inflammatory.

---

This completely reorganized and updated resource delivers concise, comprehensive, and authoritative coverage of all aspects of clinical rheumatology - with information relevant to both the trainee and experienced practitioner. Three well-organized sections - Diagnosis, Rheumatic Diseases, and Pharmacopeia for Rheumatic Diseases - address diagnosis and management for a range of adult and pediatric rheumatic disorders, including those of idiopathic, infectious, reactive, inflammatory, autoimmune, degenerative, and mechanical origin.This quick-consult covers the full scope of rheumatologic diagnosis and treatment. A wide range of diagnostic tests - including ANA, DNA, RF, ANCA and CCP antibody tests - show you what test to order and how to interpret the results. Disease-specific coverage addresses more than 140 specific rheumatic conditions, their diagnostic criteria, and treatment recommendations. The latest drugs are described in detail to help you select the best therapy for each patient. Tabbed pages and alphabetically arranged topics help you find information quickly. Structured chapter template presents information in a consistent format.
ICD-9 codes in all disease chapters assist in diagnostic coding."Fast Fact Guide to Patient Assessment" on the inside covers puts vital facts at your fingertips. New to this Edition: all new reorganization - a real time saver for the busy trainee or clinician; more consistent presentation for greater accessibility; new entries on pediatric disorders to help treat your young patients; the newest anti-rheumatic drugs, including celecoxib, rofecoxib, meloxicam, valdecoxib, leflunomide, mycophenolate, infliximab, etanercept, adalimumab, anakinra, rituximab, and many more.